[ASCO 2016: Confirmation of respective roles of docetaxel and cabazitaxel in prostate cancer patients].
Centre Oscar-Lambret, Department of Medical Oncology, 3, rue Frédéric-Combemale, 59020 Lille, France. Electronic address: n-penel@o-lambret.fr.
Nicolas
N
Penel
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000601:surgery; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; C552428:cabazitaxel